Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032045414> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2032045414 endingPage "1756" @default.
- W2032045414 startingPage "1756" @default.
- W2032045414 abstract "The recently published article, entitled “Extensive Coronary Aneurysms with Thrombosis in Resistant Kawasaki Disease” by Sivakumar and Pavithran [5], concisely delineates the limitations in the treatment of Kawasaki disease (KD). There is no one accepted treatment algorithm for treatment-refractory patients, and the efficacy of infliximab as a first-line therapy adjunct has not yet been studied. Although a retrospective study showed improvement in various clinical outcomes, use of infliximab as second-line therapy is not convincingly supported by highly powered studies [1]. As this case illustrates, the treatment of KD is neither universal nor intuitive. The efficacy of infliximab in this population would perhaps be enhanced if administered at an earlier time point, especially in children who are at high risk for resistance to therapy.Children who are resistant to first-line treatment with IVIG carry a higher risk for development of coronary artery aneurysms [4]. Therefore, to avoid such devastating outcomes, should infliximab be used as an adjunct to IVIG in the treatment of children with KD who are at high risk? These high-risk patients (male, young age, recurrence of fever) could possibly be identified with a risk stratification algorithm and may benefit from more aggressive early therapy.It has been shown that tumor-necrosis factor (TNF)-alpha inhibitors decrease inflammation and endoarteritis in murine models, specifically the inhibition of neutrophil adhesion to endothelial cells, which is seen in the early phase of vasculitis [2]. This proof of concept experiment further elucidates the role of TNF-alpha inhibitors in the treatment of panvasculitis. Based on the mechanism of endoarteritis and the success of other patients treated with infliximab, we believe that high-risk KD patients may benefit from early treatment with infliximab in conjunction with conventional IVIG therapy [3,4]. In keeping with this hypothesis, researchers at The University of California at San Diego recently completed a phase III placebo-controlled, multicenter, randomized clinical trial of infliximab plus standard therapy versus placebo plus standard therapy in children with acute KD to determine if the addition of infliximab to primary therapy can decrease the percentage of children who are resistant to therapy. Results of this study will perhaps further guide our primary management of KD." @default.
- W2032045414 created "2016-06-24" @default.
- W2032045414 creator A5039747166 @default.
- W2032045414 creator A5045920950 @default.
- W2032045414 date "2013-06-15" @default.
- W2032045414 modified "2023-09-25" @default.
- W2032045414 title "Should Infliximab be Used as an Adjuvant to IVIG in the Treatment of Children With Kawasaki Disease Who Are at High Risk for Resistance to Conventional Therapy?" @default.
- W2032045414 cites W1983306648 @default.
- W2032045414 cites W1998607827 @default.
- W2032045414 cites W2047539120 @default.
- W2032045414 cites W2319381636 @default.
- W2032045414 cites W4253099814 @default.
- W2032045414 doi "https://doi.org/10.1007/s00246-013-0731-3" @default.
- W2032045414 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3783637" @default.
- W2032045414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23771701" @default.
- W2032045414 hasPublicationYear "2013" @default.
- W2032045414 type Work @default.
- W2032045414 sameAs 2032045414 @default.
- W2032045414 citedByCount "7" @default.
- W2032045414 countsByYear W20320454142014 @default.
- W2032045414 countsByYear W20320454142016 @default.
- W2032045414 countsByYear W20320454142017 @default.
- W2032045414 countsByYear W20320454142018 @default.
- W2032045414 countsByYear W20320454142022 @default.
- W2032045414 crossrefType "journal-article" @default.
- W2032045414 hasAuthorship W2032045414A5039747166 @default.
- W2032045414 hasAuthorship W2032045414A5045920950 @default.
- W2032045414 hasBestOaLocation W20320454141 @default.
- W2032045414 hasConcept C126322002 @default.
- W2032045414 hasConcept C159654299 @default.
- W2032045414 hasConcept C177713679 @default.
- W2032045414 hasConcept C187212893 @default.
- W2032045414 hasConcept C203014093 @default.
- W2032045414 hasConcept C2776694085 @default.
- W2032045414 hasConcept C2776820930 @default.
- W2032045414 hasConcept C2777010666 @default.
- W2032045414 hasConcept C2777138892 @default.
- W2032045414 hasConcept C2777863537 @default.
- W2032045414 hasConcept C2777982462 @default.
- W2032045414 hasConcept C2778789114 @default.
- W2032045414 hasConcept C2779134260 @default.
- W2032045414 hasConcept C2781423770 @default.
- W2032045414 hasConcept C2908856526 @default.
- W2032045414 hasConcept C542903549 @default.
- W2032045414 hasConcept C71924100 @default.
- W2032045414 hasConceptScore W2032045414C126322002 @default.
- W2032045414 hasConceptScore W2032045414C159654299 @default.
- W2032045414 hasConceptScore W2032045414C177713679 @default.
- W2032045414 hasConceptScore W2032045414C187212893 @default.
- W2032045414 hasConceptScore W2032045414C203014093 @default.
- W2032045414 hasConceptScore W2032045414C2776694085 @default.
- W2032045414 hasConceptScore W2032045414C2776820930 @default.
- W2032045414 hasConceptScore W2032045414C2777010666 @default.
- W2032045414 hasConceptScore W2032045414C2777138892 @default.
- W2032045414 hasConceptScore W2032045414C2777863537 @default.
- W2032045414 hasConceptScore W2032045414C2777982462 @default.
- W2032045414 hasConceptScore W2032045414C2778789114 @default.
- W2032045414 hasConceptScore W2032045414C2779134260 @default.
- W2032045414 hasConceptScore W2032045414C2781423770 @default.
- W2032045414 hasConceptScore W2032045414C2908856526 @default.
- W2032045414 hasConceptScore W2032045414C542903549 @default.
- W2032045414 hasConceptScore W2032045414C71924100 @default.
- W2032045414 hasIssue "7" @default.
- W2032045414 hasLocation W20320454141 @default.
- W2032045414 hasLocation W20320454142 @default.
- W2032045414 hasLocation W20320454143 @default.
- W2032045414 hasLocation W20320454144 @default.
- W2032045414 hasOpenAccess W2032045414 @default.
- W2032045414 hasPrimaryLocation W20320454141 @default.
- W2032045414 hasRelatedWork W1985991902 @default.
- W2032045414 hasRelatedWork W1996124248 @default.
- W2032045414 hasRelatedWork W2030172248 @default.
- W2032045414 hasRelatedWork W2032045414 @default.
- W2032045414 hasRelatedWork W2032920304 @default.
- W2032045414 hasRelatedWork W2091688588 @default.
- W2032045414 hasRelatedWork W2092194066 @default.
- W2032045414 hasRelatedWork W2093609357 @default.
- W2032045414 hasRelatedWork W4225828223 @default.
- W2032045414 hasRelatedWork W4498736 @default.
- W2032045414 hasVolume "34" @default.
- W2032045414 isParatext "false" @default.
- W2032045414 isRetracted "false" @default.
- W2032045414 magId "2032045414" @default.
- W2032045414 workType "article" @default.